What was CITIUS ONCOLOGY, INC.'s revenue in Q1 FY2026?

CITIUS ONCOLOGY, INC. reported total revenue of $3.9M in Q1 FY2026.

What was CITIUS ONCOLOGY, INC.'s net profit in Q1 FY2026?

CITIUS ONCOLOGY, INC. reported net profit of $-5.5M in Q1 FY2026, a net margin of -140.3%.

What were CITIUS ONCOLOGY, INC.'s margins in Q1 FY2026?

CITIUS ONCOLOGY, INC. had gross margin of 80.0% and operating margin of -133.2% in Q1 FY2026.

What was CITIUS ONCOLOGY, INC.'s EPS in Q1 FY2026?

CITIUS ONCOLOGY, INC. reported diluted EPS of $-0.06 in Q1 FY2026.

CITIUS ONCOLOGY, INC.CTOREarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Deep Analysis

Citius Oncology, Inc. is a late-stage biopharmaceutical company focused on developing innovative targeted therapies for cancer patients. Its core pipeline covers treatments addressing unmet medical needs in hematologic malignancies and solid tumors, primarily serving North American and global oncology care markets.

Q1 2026

Revenue

$3.9M

Gross Profit

$3.2M

Operating Profit

$-5.3M

Net Profit

$-5.5M

Gross Margin

80.0%

Operating Margin

-133.2%

Net Margin

-140.3%

YoY Growth

N/A

EPS

$-0.06

CITIUS ONCOLOGY, INC. Q1 FY2026 Financial Summary

CITIUS ONCOLOGY, INC. reported revenue of $3.9M for Q1 FY2026, with a net profit of $-5.5M (up 16.9% YoY) (-140.3% margin). Cost of goods sold was $789.2K, operating expenses totaled $8.4M.

Key Financial Metrics

Total Revenue	$3.9M
Net Profit	$-5.5M
Gross Margin	80.0%
Operating Margin	-133.2%
Report Period	Q1 FY2026

Income Statement

	Q1 2026
Revenue	$3.9M
YoY Growth	N/A

Balance Sheet

	Q1 2026
Assets	$110.0M
Liabilities	$51.6M
Equity	$58.4M

Cash Flow

	Q1 2026
Operating CF	$-7.4M